Jean-François Arrighi
Plus aucun poste en cours
Provenance du réseau au premier degré de Jean-François Arrighi
Entité | Type d'entité | Industrie | |
---|---|---|---|
Public Company | Biotechnology | 3 |
Graphique Sociétés connectées au second degré
Relation dans plusieurs entreprises
Sociétés connectées à Jean-François Arrighi via son réseau personnel
Société | Secteur | Personnes liées | Poste principal |
---|---|---|---|
TRANSGENE | Biotechnology | Director/Board Member | |
Fujirebio Europe NV
Fujirebio Europe NV Medical SpecialtiesHealth Technology Fujirebio Europe NV develops and markets diagnostic products to improve therapy management and patient health. It focuses on molecular diagnostics and multiparameter testing. The firm also provides LUMIPULSE G1200, an automated chemiluminescent enzyme immunoassay system; LUMIPULSE G600 II, an automated benchtop CLEIA system, routine and novel markers for the oncology sector. The company was founded in 1985 by Philippe Leboulch and is headquartered in Ghent, Belgium. | Medical Specialties | President | |
BIOMÉRIEUX | Medical Specialties | Director/Board Member | |
TSGH SAS
TSGH SAS Financial ConglomeratesFinance TSGH SAS operates as an investment holding company. The company is headquartered in Lyon, France. | Financial Conglomerates | Chief Executive Officer | |
Massachusetts Institute of Technology | College/University | Doctorate Degree | |
INNATE PHARMA | Pharmaceuticals: Major | Founder | |
bioMérieux, Inc.
bioMérieux, Inc. Medical SpecialtiesHealth Technology bioMérieux, Inc. develops in-vitro diagnostics solutions. It offers microbiological testing solutions for medical and industrial applications. The company was founded on December 31, 1986 and is headquartered in Durham, NC. | Medical Specialties | Chairman | |
Advanced BioScience Laboratories, Inc.
Advanced BioScience Laboratories, Inc. Medical/Nursing ServicesHealth Services Advanced BioScience Laboratories, Inc. provides contract manufacturing and laboratory research services to advance leading vaccines and therapies from clinical development to the commercial market. It focuses on the development of therapeutics, vaccines, and other biologic products. The company was founded in 1961 and is headquartered in Rockville, MD. | Medical/Nursing Services | Director/Board Member | |
University of Lyon | College/University | Doctorate Degree | |
Centre National de la Recherche Scientifique
Centre National de la Recherche Scientifique General GovernmentGovernment Centre National de la Recherche Scientifique provides scientific research services. The firm engages in the research capable of advancing knowledge and bringing social, cultural, and economic benefits for society. The company was founded in 1939 and is headquartered in Paris, France. | General Government | Corporate Officer/Principal | |
bioMERIEUX Benelux SANV
bioMERIEUX Benelux SANV Medical SpecialtiesHealth Technology bioMERIEUX Benelux SANV is specialized in the field of in vitro diagnostics for medical and industrial applications. The group designs, develops, manufactures and markets systems used in clinical applications (diagnosis of infectious diseases based on the analysis of biological samples) and industrial applications (the analysis of industrial or environmental samples to determine its microbiological quality). The company was founded in 1979 and is headquartered in Bruxelles, Belgium | Medical Specialties | Director/Board Member | |
Institut Mérieux SA
Institut Mérieux SA BiotechnologyHealth Technology Institut Mérieux SA provides solutions for multifactorial management of diseases. The firm provides solutions for diseases, including tuberculosis, liver cancer and hepatitis. It specializes in the field human and veterinary of vaccines. It operates under the activities of diagnostics, immunotherapy and nutrition. The company was founded by Marcel Mérieux in 1897 and is headquartered Lyon, France. | Biotechnology | Corporate Officer/Principal Chief Tech/Sci/R&D Officer | |
Synergie Lyon Cancer
Synergie Lyon Cancer Miscellaneous Commercial ServicesCommercial Services Synergie Lyon Cancer provides health care services. It focuses on research efforts on cancer escape, apoptosis and senescence and Immune surveillance. The company was founded in 2007 and is headquartered in Lyon, France. | Miscellaneous Commercial Services | Director/Board Member | |
École Supérieure de Chimie Physique Électronique | College/University | Director/Board Member | |
Transgene, Inc. | Director/Board Member | ||
Lyonbiopôle
Lyonbiopôle Miscellaneous Commercial ServicesCommercial Services Lyonbiopôle is a competitiveness cluster located in Lyon, France. The French company serves as a catalyst for the health innovation ecosystem by connecting, developing, and promoting it. Lyonbiopôle's main focus is on the health sector, and it works to ensure that the ecosystem is thriving and innovative. | Miscellaneous Commercial Services | Chairman | |
Fondation FINOVI | Director/Board Member | ||
Platine Pharma Services SAS
Platine Pharma Services SAS Medical/Nursing ServicesHealth Services Based in Lyon within the Center of excellence in Infectious Diseases, Platine Pharma Services is an essential source of immune information for scientists and clinicians. From protocol support to regulatory reports, the company designs, performs and interprets complex molecular and cellular assays. Platine actively supports the development of in-vitro diagnostic, cosmetic and therapeutic product candidates, highlighting key markers and features in both normal and pathological conditions, and guiding decisions at each development stage. Using state-of-the-art technologies such as multi-parametric flow cytometry, Singulex, Luminex, Mesoscale Discovery, ELISpot or ELISA, Platine Pharma Services offers a fit-for-purpose approach to its customers and partners. | Medical/Nursing Services | Director/Board Member | |
Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd.
Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd. Miscellaneous Commercial ServicesCommercial Services Transgene Tasly (Tianjin) Biopharmaceutical Co., Ltd. engages in theresearch and development, and manufacture of immunotherapies for the treatment of oncology and infectious diseases. Its business scope includes biopharmaceutical technology development, technology transfer, and related technical advisory services. The company was founded on July 26, 2010 and is headquartered in Tianjin, China. | Miscellaneous Commercial Services | Director/Board Member | |
BioAster
BioAster Miscellaneous Commercial ServicesCommercial Services BioAster operates as a research institute. The private company is based in Lyon, France. The CEO of the French company is Nathalie Garçon. | Miscellaneous Commercial Services | Chairman | |
Global Virus Network
Global Virus Network Miscellaneous Commercial ServicesCommercial Services Global Virus Network conducts research on essential and critical defense against viral diseases. The non-profit company is based in Baltimore, MD. The company was founded by William Walmsley Hall and Robert C. Gallo. | Miscellaneous Commercial Services | Director/Board Member | |
Harvard Business School | College/University | Undergraduate Degree | |
Fabentech SAS
Fabentech SAS Medical/Nursing ServicesHealth Services Fabentech SAS developes immunotherapeutic solutions for emerging infectious diseases as well as for certain drug intoxications. Its products include infography development, Lassa(FBH-003) and other emerging diseases. The company was founded by Bertrand Lepine on June 5, 2009 and is headquartered in Lyon, France. | Medical/Nursing Services | Chairman | |
Transgene Biopharmaceutical Technology (Shanghai) Co. Ltd. | Director/Board Member | ||
NH THERAGUIX SAS | Pharmaceuticals: Major | Director/Board Member | |
Jalon Therapeutics
Jalon Therapeutics Pharmaceuticals: MajorHealth Technology Jalon Therapeutics is a French company that aims to develop innovative therapies to treat cancer by inactivating vital tumor signaling pathways. Jalon Therapeutics is based in Paris, France and manages an extensive candidate portfolio of drug candidates infused by its unique expertise in AAC-11 biology. The company leverages their deep understanding of stress-related protein-protein interaction networks that sustain the malignant phenotype while not being necessary for normal cells. The company's lead candidate, JRT39, is the first-in-class drug developed for the treatment of hard-to-treat cancers. The company is building a drug discovery platform to develop other candidates derived from AAC-11 and AAC-11 partners for the treatment of cancer. Jalon Therapeutics raised a pre-seed in 2022, leveraged by non-dilutive and quasi-equity fundings from public institutions. The company's growth ambition is to raise a seed immediately followed by a series A to finance up to the clinical proof of concept of their lead candidate JRT39. The company was founded in 2021 by Jérôme Tiollier, Jean-Luc Poyet, Prof. Martine Bagot, Prof. Hervé Dombret, Jean-Christophe Rain, and Philippe Salphati. The CEO is David Loison. | Pharmaceuticals: Major | Director/Board Member | |
PHAXIAM THERAPEUTICS S.A. | Pharmaceuticals: Major | Director/Board Member |
Statistiques
Internationale
France | 19 |
Etats-Unis | 7 |
Belgique | 3 |
Chine | 3 |
Sectorielle
Health Technology | 12 |
Commercial Services | 6 |
Health Services | 4 |
Consumer Services | 4 |
Finance | 3 |
Opérationnelle
Director/Board Member | 19 |
Independent Dir/Board Member | 5 |
Chairman | 5 |
Corporate Officer/Principal | 3 |
Undergraduate Degree | 2 |
Relations les plus connectées
Insiders | |
---|---|
Philippe Archinard | 24 |
Marc Bonneville | 7 |
Thomas Rückle | 1 |
- Bourse
- Insiders
- Jean-François Arrighi
- Connexions Sociétés